RxDoctor Payments Data

Srihari Ravi, MD

Cardiovascular Disease · Roseville, MINPI 1184626731

Payments from drug & device makers

$1,814in general payments, 2019–2025

Across 66 payments — averaging $27.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$666
  • Boston Scientific$233
  • Abbott$201
  • Novartis$95
  • E.r. Squibb & Sons, L.L.C.$94
  • Johnson & Johnson$89
  • plus $435 from 15 others

What the payments were for

  • Food & beverage$1,814100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,814 in reported general payments places this provider in the 40th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$189,098
Medicare patients
940
Services billed
3,785

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban552$482,478
EntrestoSacubitril/Valsartan265$261,321
JardianceEmpagliflozin214$154,129
Repatha SureclickEvolocumab122$134,717
XareltoRivaroxaban90$62,327
BrilintaTicagrelor90$62,312
FarxigaDapagliflozin Propanediol63$53,225
Praluent PenAlirocumab53$40,773
Metoprolol Succinate953$16,417
Rosuvastatin Calcium821$14,050
Ranolazine ErRanolazine127$11,841
Isosorbide Dinitrate206$11,430
Ezetimibe308$7,460
Olmesartan Medoxomil218$5,739
ClopidogrelClopidogrel Bisulfate274$5,574

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$482,478552 claims
NovartisEntresto$95$261,321265 claims
Boehringer IngelheimJardiance$32$154,129214 claims
Johnson & JohnsonXarelto$89$62,32790 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Roseville

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →